Bariatric Surgery

Bariatric surgery is an option for people who are severely obese and cannot lose weight by traditional means or who suffer from serious obesity-related health problems. The operation promotes weight loss and reduces the risk of type 2 diabetes by restricting food intake.

What is Bariatric Surgery?

Exercise and diet alone often fails to effectively treat people with extreme and excessive obesity. Bariatric surgery is an operation that is performed in order to help such individuals lose weight. Evidence suggests that bariatric surgery may lower death rates for patients with severe obesity, especially when coupled with healthy eating and lifestyle changes after surgery.

Bariatric Surgery Side Effects

Weight Loss After Bariatric Surgery

Metabolic Syndrome and Bariatric Surgery

Taste Changes Following Bariatric Surgery

Bariatric Surgery Types

Bariatric Surgery Research

Diet After Bariatric Surgery

Latest Bariatric Surgery News and Research

The role of gut bacteria in sustained diabetes improvement

Changes in gut microbiota after bariatric surgery are strongly linked to altered metabolic health and sustained improvement in type 2 diabetes, according to a study led by researchers at the University of Gothenburg.

7 May 2026

Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

6 May 2026

Bariatric surgery outperforms GLP-1 medications for obesity disease remission

Metabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like peptide-1 receptor agonists (GLP-1s), according to one of the largest and most comprehensive real-world comparisons of the two treatments.

6 May 2026

U.S. bariatric surgery rates drop significantly amid GLP-1 surge

The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first time since 2020, a more than 20% decline from the prior year, according to new research presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Bariatric surgery improves outcomes for patients with obesity and chronic kidney disease

Metabolic and bariatric surgery, also known as weight-loss surgery, dramatically improves outcomes for patients with obesity and chronic kidney disease (CKD), significantly reducing the risk of kidney failure, major cardiovascular events and death, according to new research presented here today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

GLP-1 use surges as surgery rates drop for severe obesity

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially -- from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 -- according to a new real-world analysis presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Bariatric surgery costs significantly less than GLP-1 drugs over two years

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to a new research presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

GLP-1 drugs combined with surgery yield superior weight loss results

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Prediabetes leaves lasting fat tissue changes after bariatric surgery

Prediabetes may leave a lasting molecular "footprint" on adipose (fat) tissue which appears to make maintaining weight loss after bariatric surgery more difficult, according to new research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

22 Apr 2026

High-fat, low-carbohydrate diet may improve beta-cell function in patients with type 2 diabetes

People with type 2 diabetes on a high-fat, low-carbohydrate diet may have a better chance of reversing their diabetes than those on a low-fat diet, according to a small study published in the Journal of the Endocrine Society.

21 Apr 2026

Evidence shows ACA’S mandated benefits alone don’t drive up costs. The debate continues.

In January, when President Donald Trump unveiled his one-page outline to address health care spending, dubbed "The Great Healthcare Plan," he specifically mentioned the Affordable Care Act's role in driving up costs.

18 Mar 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026

New polygenic risk scores improve prediction of metabolic disease outcomes

Type 2 diabetes (T2D) and obesity are metabolic conditions with many causes, including overlapping and distinct genetic features.

16 Mar 2026

UVA researcher receives $3.4 million grant to improve weight-management programs

A University of Virginia School of Medicine researcher has received $3.4 million from the National Institutes of Health to increase the availability of weight-management programs that offer beneficial personalized feedback.

12 Mar 2026

Real-world study shows modest weight regain after GLP-1 discontinuation

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings.

12 Mar 2026

Ozempic users continue treatment when weight loss works despite side effects

A study on Ozempic for weight loss reveals user satisfaction is driven by efficacy, despite common gastrointestinal side effects impacting treatment adherence.

13 Feb 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026